Navigation Links
BioMedomics, Inc. Closes $690K Round of Financing
Date:1/14/2014

Research Triangle Park, NC (PRWEB) January 14, 2014

BioMedomics, Inc., a Point of Care (POC) diagnostic company focusing on ultra-sensitive POC diagnostic platforms and novel disease specific POC tests, announced today that it has closed on their first round of financing netting a total of $690,000. The investment is from private investors and is the first outside equity capital in the company. This group of private investors has significant successful experience in early investments in diagnostics companies and includes Tom Roberg who was most recently Vice Chairman of the diagnostic company Advanced Liquid Logic.

Approximately $6 million in non-dilutive monies have already been invested in BioMedomics technologies enabling the company to initiate development of a range of ultra-sensitive diagnostic platforms and novel disease specific tests including acetaminophen overdose, sickle cell disease, and alpha-thalassemia, among others. This investment of outside equity capital will allow the company to meet several significant developmental milestones as well as round out its scientific staff.

“We are thrilled to have such strong support and validation of our technologies from these experienced diagnostics investors,” said Dr. Frank Wang, CEO of BioMedomics, “Our prior grant funding has made it possible to establish an excellent group of diagnostic products. This investment will provide us the ability to focus our efforts on the next stage developmental milestones necessary for additional non-dilutive grants or follow-on capital. We are extremely excited about the potential this funding brings to BioMedomics.”

About BioMedomics, Inc. – BioMedomics was founded in 2006 and is located in Research Triangle Park, NC. BioMedomics is developing advanced highly sensitive and quantitative rapid POC diagnostic platforms and novel disease specific diagnostic tests for the $16 billion POC diagnostic market. The company’s goal is to make POC testing widely accessible with the same level of sensitivity and quantitation as complex and expensive central lab tests.

The core competencies of the company are a strong combination of biology, biochemistry, and biomedical engineering expertise that underline its technology and product development. To meet the increasing need for improved sensitivity in POC diagnostics the company is developing its next generation Time Resolved and Nanotube platforms. Both of these platforms have the potential for sensitivity below the one picogram/mL level. The company also has a particular expertise in developing POC tests for Drugs of Abuse/Overdose and hemoglobinopathies. Tests currently under development include acetaminophen overdose, Sickle Cell Disease, Alpha Thalassemia, and Heparin Induced Thrombocytopenia, among others.

Read the full story at http://www.prweb.com/releases/2014/01/prweb11480517.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Radius Closes $27.65 Million Second Tranche of Previously Announced Financing
2. Avaxia Biologics, Inc. Closes $4.1 Million Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
3. OncoSec Closes $7.75 Million Public Offering
4. AyoxxA Biosystems Closes Series A Financing Round
5. Enviva Closes on $120 Million Senior Secured Credit Facility
6. Avelas Biosciences Closes $7.65 Million Series A, Advances Real-Time Tumor Visualization Technology Toward Development
7. Biscayne Pharmaceuticals Closes $1.5 Million Financing To Advance Recent Discoveries Of Pioneering Endocrine Drug Researcher
8. Nasseo, Inc. Joins BioInspire™ Medical Technology Incubator, Closes Seed Funding Round
9. Aratana Closes $10 Million Non-Dilutive Financing with Square 1 Bank
10. iBio, Inc. closes $4.2 million public offering and terminates At-the-market offering
11. Westchester Library Closes Due to Bed Bugs, My Cleaning Products Recommends Pesticide-Exempt Bed Bug Spray to Officials and Others Suffering from the Pests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ... , ... The Society for Immunotherapy of Cancer (SITC) strongly opposes the proposed ... fiscal year 2018 budget request. , This proposal calls for a ... roughly 20% of its total budget. If applied proportionally across NIH, funding for the ...
(Date:3/22/2017)... , March 22, 2017  RXi Pharmaceuticals ... innovative therapeutics that address significant unmet medical needs, ... Chief Business Officer, will present at the 5th ... will provide a platform to present to and ... leading pharmaceutical and biotech companies as well as ...
(Date:3/20/2017)... ... March 20, 2017 , ... ... and biotech companies, recently announced it will debut a brand new pressure vessel, ... The intelliVessel is controlled by a touch screen panel and features other revolutionary ...
(Date:3/20/2017)... , ... March 20, 2017 , ... The fourth annual ... while innovating to make an extraordinary impact on peoples’ lives, launches today. Sponsored by ... challenge every 5 weeks and awards thousands in cash prizes to engineers, inventors and ...
Breaking Biology Technology:
(Date:2/14/2017)... N.C. , Feb. 14, 2017  Wake Forest ... M.D., as its new chief executive officer (CEO). Freischlag ... CEO John D. McConnell , M.D., who last ... position at the Medical Center, after leading it since ... the full scope of Wake Forest Baptist,s academic health ...
(Date:2/10/2017)... Feb 10, 2017 Research and ... "Personalized Medicine - Scientific and Commercial Aspects" to ... ... Diagnosis is integrated with therapy for selection of treatment as ... detection and prevention of disease in modern medicine. Biochip/microarray technologies ...
(Date:2/8/2017)... 2017  Aware, Inc. (NASDAQ: AWRE ), a ... results for its quarter and year ended December 31, 2016. ... was $3.9 million compared to $6.9 million in the same ... 2016 was $0.6 million compared to $2.6 million in the ... of 2016 was $0.5 million, or $0.02 per diluted share, ...
Breaking Biology News(10 mins):